No Data
No Data
Ark Pharmacy (06086.HK) will hold a board of directors meeting on August 28 to approve the interim performance.
On August 16th, Gelonhui announced that Ark Pharmacy (06086.HK) will convene a board meeting on August 28th, 2024 to consider and approve the mid-term performance of the company and its affiliates for the six months ending June 30th, 2024, as well as to consider distributing interim dividends (if any).
ARK Pharmacies Limited (06086.HK) plans to hold a board of directors meeting on August 28 to approve its mid-year performance.
Ark Pharmacy (06086.HK) announced on August 16th that the company will hold a board of directors meeting on Wednesday, August 28, 2024, to consider and approve the company and its subsidiaries' six-month interim performance as of June 30th, 2024, and its publication, including the consideration of distributing interim dividends (if any), and handling other matters.
FANGZHOU JIANKE: DATE OF BOARD MEETING
Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
ARK Health (06086.HK): stable pricing action, end of stable pricing period and expiration of excess share subscription rights.
On August 5th, Guolonghui announced that the stable price period for global sales of Ark Pharmacy (06086.HK) has ended on August 3rd, 2024 (i.e. 30 calendar days from the deadline for submitting the Hong Kong public offering application). The overall coordinator (for itself and on behalf of international underwriters) did not exercise the over-allotment option, which expired on August 3rd, 2024.
Carrying on traditions and innovation, Ark Pharmacy collaborates with Guangzhou Baiyunshan to create a digital medical and health intelligence blueprint.
Arca Health and Guangzhou Baiyunshan collaborate to create a digital medical and health intelligence blueprint.
No Data